Abstract 3106
Background
Overall survival of patients (pts) with metastatic colorectal cancer (mCRC) has been increasing over the last decades. “Drug holiday” strategies were introduced by the oncologists to reduce toxicity. We aimed at studying what are the clinico-pathological and treatment factors that drive the decision to propose a “drug holiday” in first line.
Methods
This is a retrospective series of consecutive pts affected by mCRC treated with first line chemotherapy. The pts included were treated from 1/1/2005 to 15/03/2017 at University Hospital of Udine and IRCCS CRO of Aviano, Italy. A “drug Holiday” was defined as 56 or more consecutive days without chemotherapy during first-line. Upfront metastasectomy were excluded. Logistic regression was used to find association between predictors and “holiday offer” in univariate and multivariate analysis.
Results
A total of 648 pts were included. In detail, 215 received a drug holiday (33.2%) while 433 (66.8%) received continuous treatment. In univariate analysis, the variables associated with holiday were: non-upfront metastasectomy (OR 11.8, IC 95% 6.62-22.6, p < 0.001), thermoablation (OR 6.08, IC 95% 3.19-11.58, p < 0.001), primary tumor (OR 2.79, IC 95% 1.79-4.34, p < 0.001), G3-G4 pathological grade (OR 1.49, IC 95% 1.01-2.19, p = 0.046), adjuvant CT (OR 1.54,IC 95% 1.06-2.33, p = 0.023). Adjuvant RT (OR 1.62, IC 95% 0.99-2.62, p = 0.051) showed a trend towards association. More than one metastatic site at diagnosis (OR 0.59, IC 95% 0.42-0.83, p = 0.003) and nodal involvement (OR 0.57, IC 95%, 0.34-0.95, p = 0.032) were associated to continuous treatment. In multivariate analysis, only first line non-upfront metastasectomy (OR 9.89, IC95% 4.38-22.33, p < 0.001), thermoablation (OR 4.48, IC95% 1.97-10.19, p < 0.001) and primary tumor resection (OR 2.43, IC95% 1.14-5.19, p = 0.022) were independently associated with drug-holiday.
Conclusions
In our cohort, clinicians were more prone to propose a drug holiday in pts who had received non-upfront metastasectomy or thermo-ablation or were treated on their primary tumor. Having more than one site of metastasis at the beginning of 1st line and nodal involvement favored continuous therapy.
Clinical trial identification
Legal entity responsible for the study
ASUIUD- Azienda Ospedaliero-Universitaria di Udine, Dipertimento di Oncologia.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract